UY37003A - Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion - Google Patents

Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion

Info

Publication number
UY37003A
UY37003A UY0001037003A UY37003A UY37003A UY 37003 A UY37003 A UY 37003A UY 0001037003 A UY0001037003 A UY 0001037003A UY 37003 A UY37003 A UY 37003A UY 37003 A UY37003 A UY 37003A
Authority
UY
Uruguay
Prior art keywords
compositions
methods
cytoquine
immunor
regulation
Prior art date
Application number
UY0001037003A
Other languages
English (en)
Inventor
Michael Didonato
Shelly Meeusen
Glen Spraggon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57543103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY37003(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY37003A publication Critical patent/UY37003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta descripción proporciona composiciones de anticuerpo injertadas con citoquina, incluyendo, por ejemplo, constructos injertados que se unen a y estimulan la señalización intracelular por un miembro de la super-familia del receptor de interleucina, y estimulan la señalización. Composiciones proporcionadas encuentran uso en mejora de respuestas de células anti-inflamatorias, y relativamente reducen efectos pro-inflamatorios en el tratamiento, mejora, prevención de trastornos relacionados con el sistema inmune que pueden ser contrarrestados con una respuesta anti-inflamatoria aumentada. Se proporcionan polinucleótidos y vectores que codifican tales moléculas y células huésped capaces de producir moléculas, así como también métodos de fabricación y uso de composiciones.
UY0001037003A 2015-12-04 2016-12-01 Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion UY37003A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562263008P 2015-12-04 2015-12-04

Publications (1)

Publication Number Publication Date
UY37003A true UY37003A (es) 2017-06-30

Family

ID=57543103

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037003A UY37003A (es) 2015-12-04 2016-12-01 Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion

Country Status (25)

Country Link
US (3) US10144768B2 (es)
EP (1) EP3383891A1 (es)
JP (2) JP6794448B2 (es)
KR (2) KR102213790B1 (es)
CN (1) CN108602870A (es)
AR (1) AR106908A1 (es)
AU (1) AU2016362777B2 (es)
BR (1) BR112018010937A2 (es)
CA (1) CA3006477A1 (es)
CL (1) CL2018001427A1 (es)
CO (1) CO2018005678A2 (es)
CU (1) CU20180047A7 (es)
EA (1) EA201891341A1 (es)
EC (1) ECSP18041733A (es)
IL (1) IL259529A (es)
MA (1) MA43372A (es)
MX (1) MX2018006778A (es)
PE (1) PE20181358A1 (es)
PH (1) PH12018501160A1 (es)
RU (1) RU2018124307A (es)
SA (1) SA518391711B1 (es)
SG (1) SG11201804259UA (es)
TW (1) TW201726716A (es)
UY (1) UY37003A (es)
WO (1) WO2017093947A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018215937A1 (en) * 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
JOP20190271A1 (ar) * 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
EP3630162A1 (en) * 2017-05-24 2020-04-08 Novartis AG Antibody-cytokine engrafted proteins and methods of use
CN109521192B (zh) * 2018-11-27 2021-07-13 柏荣诊断产品（上海）有限公司 一种提高胶乳比浊试剂检测灵敏度的方法
WO2020181235A1 (en) * 2019-03-06 2020-09-10 Deka Biosciences, Inc. Il-10 variant molecules and methods of treating inflammatory disease and oncology
MA56130A (fr) * 2019-06-10 2022-04-13 Takeda Pharmaceuticals Co Procédés de culture cellulaire et compositions pour la production d'anticorps
JP7497417B2 (ja) * 2019-07-08 2024-06-10 プロジェン・カンパニー・リミテッド 新規ｉｌ－１０変異体タンパク質及びその用途
CN110472294B (zh) * 2019-07-19 2022-09-30 河南科技大学 一种嫁接涡旋光束的掩模板的设计方法
MX2023000948A (es) 2020-07-20 2023-04-14 Deka Biosciences Inc Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10).
CN116615462A (zh) 2020-11-23 2023-08-18 诺华股份有限公司 抗体构建体的表达技术
JP2024517711A (ja) 2021-04-29 2024-04-23 ノバルティス アーゲー 高シアル酸付加細胞
CN116063570A (zh) * 2021-11-02 2023-05-05 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
CN118221829A (zh) * 2022-12-21 2024-06-21 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
EP0793504B1 (en) 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US7279462B1 (en) 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
WO2002044197A2 (en) 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
AU3400102A (en) 2000-12-05 2002-06-18 Alexion Pharma Inc Rationally designed antibodies
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
ATE382367T1 (de) 2002-04-09 2008-01-15 Univ Missouri Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
CA2481437A1 (en) 2002-04-09 2003-10-16 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US8603472B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2004089407A2 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2004108078A2 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals Inc. Rationally designed antibodies
AU2005207003C1 (en) 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
PL3540062T3 (pl) 2004-11-16 2021-12-27 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
ES2689274T3 (es) 2008-01-03 2018-11-13 The Scripps Research Institute Dirección de anticuerpos mediante un dominio de reconocimiento modular
MX2011008936A (es) * 2009-02-24 2011-09-21 Alexion Pharma Inc Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
KR20120053042A (ko) 2009-08-17 2012-05-24 로슈 글리카트 아게 표적화된 면역접합체
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8956607B2 (en) 2009-11-30 2015-02-17 Biotest Ag Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE)
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
WO2012045334A1 (en) 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
CN103476433A (zh) 2011-02-10 2013-12-25 罗切格利卡特公司 改良的免疫疗法
MY190604A (en) 2011-02-10 2022-04-27 Roche Glycart Ag Mutant interleukin-2 polypeptides
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2862979A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US10774132B2 (en) * 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
ES2848732T3 (es) 2012-08-07 2021-08-11 Roche Glycart Ag Inmunoterapia mejorada
SG11201408526SA (en) 2012-08-08 2015-03-30 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
EP2943512A4 (en) 2013-01-11 2016-06-01 California Inst Biomedical Res FUSION BOVINE ANTIBODIES
WO2014138725A1 (en) * 2013-03-08 2014-09-12 Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2015006736A2 (en) 2013-07-11 2015-01-15 The California Institute For Biomedical Research Coiled coil immunoglobulin fusion proteins and compositions thereof
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
RU2016135788A (ru) * 2014-02-06 2018-03-07 Ф.Хоффманн-Ля Рош Аг Иммуноконъюгаты интерлейкина 10
EA034350B1 (ru) 2014-02-06 2020-01-30 Ф.Хоффманн-Ля Рош Аг Слитые белки, содержащие интерлейкин-2, и их применения

Also Published As

Publication number Publication date
US10144768B2 (en) 2018-12-04
CU20180047A7 (es) 2018-07-05
KR20210016479A (ko) 2021-02-15
KR20180081622A (ko) 2018-07-16
CL2018001427A1 (es) 2018-07-27
EA201891341A1 (ru) 2018-11-30
CO2018005678A2 (es) 2018-06-12
AR106908A1 (es) 2018-02-28
KR102213790B1 (ko) 2021-02-09
TW201726716A (zh) 2017-08-01
RU2018124307A (ru) 2020-01-14
US20170158747A1 (en) 2017-06-08
MX2018006778A (es) 2018-08-01
AU2016362777B2 (en) 2020-01-30
AU2016362777A1 (en) 2018-06-07
IL259529A (en) 2018-07-31
RU2018124307A3 (es) 2020-05-13
US20220127321A1 (en) 2022-04-28
PH12018501160A1 (en) 2019-01-21
CN108602870A (zh) 2018-09-28
WO2017093947A1 (en) 2017-06-08
SG11201804259UA (en) 2018-06-28
JP2019505173A (ja) 2019-02-28
JP2021040637A (ja) 2021-03-18
BR112018010937A2 (pt) 2018-12-04
US11136366B2 (en) 2021-10-05
EP3383891A1 (en) 2018-10-10
MA43372A (fr) 2018-10-10
ECSP18041733A (es) 2018-06-30
US20190241636A1 (en) 2019-08-08
CA3006477A1 (en) 2017-06-08
JP6794448B2 (ja) 2020-12-02
SA518391711B1 (ar) 2021-07-27
PE20181358A1 (es) 2018-08-22

Similar Documents

Publication Publication Date Title
UY37003A (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
ECSP17005276A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
UY36862A (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
UY36154A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
AR099289A1 (es) Proteínas de fusión de interleucina-2 y usos de las mismas
UY37738A (es) Proteínas injertadas de anticuerpo-citoquina y métodos de uso para trastornos inmunes relacionados
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
CL2016002088A1 (es) Anticuerpos monoclonales biespecificos contra il-13/il-17; ácido nucleico; célula huésped; método de producción del anticuerpo; inmunoconjugados; formulación farmacéutica; y usos de los anticuerpos biespecíficios para el tratamiento del asma moderada a severa y/o asma eosinofílica.
CL2018000103A1 (es) Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
CL2016002245A1 (es) Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica
DOP2018000019A (es) Inmunoconjugados de il22
AR105945A1 (es) Composiciones y métodos usados para aumentar la respuesta inmune y terapia del cáncer
AR101592A1 (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cd123
AR103227A1 (es) Anticuerpos anti-csf1r para el tratamiento de svp
CL2012001309A1 (es) Anticuerpos humanizados contra el receptor alfa de la interleucina 22 (il-22ra) humana; polinucleotido que codifica tanto la cadena pesada como la cadena liviana de dicho anticuerpo; vector y celula hospedera que comprende dicho polinucleotido; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratar soriasis, artritis soriatica o dermatitis atópica.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221212